Our analyses of an external HCC cohort treated with anti-PD-1 monotherapy revealed a trend toward enrichment of cytotoxic features in CXCR3+CD8+ T cells among responders after anti-PD-1 monotherapy, which is in agreement with our findings regarding CD8+ T cell responses. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.